Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.
Pohl L, Friedhoff J, Jurcic C, Teroerde M, Schindler I, Strepi K, Schneider F, Kaczorowski A, Hohenfellner M, Duensing A, Duensing S. Pohl L, et al. Among authors: duensing a, duensing s. Front Oncol. 2022 May 10;12:889686. doi: 10.3389/fonc.2022.889686. eCollection 2022. Front Oncol. 2022. PMID: 35619925 Free PMC article. Review.
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S. Pecqueux C, et al. Among authors: duensing a, duensing s. Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7. Urol Oncol. 2018. PMID: 29887238
Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
Li J, Pohl L, Schüler J, Korzeniewski N, Reimold P, Kaczorowski A, Hou W, Zschäbitz S, Nientiedt C, Jäger D, Hohenfellner M, Duensing A, Duensing S. Li J, et al. Among authors: duensing a, duensing s. Biomedicines. 2021 May 31;9(6):627. doi: 10.3390/biomedicines9060627. Biomedicines. 2021. PMID: 34072926 Free PMC article.
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C, Budczies J, Endris V, Kirchner M, Schwab C, Jurcic C, Behnisch R, Hoveida S, Lantwin P, Kaczorowski A, Geisler C, Dieffenbacher S, Falkenbach F, Franke D, Görtz M, Heller M, Himmelsbach R, Pecqueux C, Rath M, Reimold P, Schütz V, Simunovic I, Walter E, Hofer L, Gasch C, Schönberg G, Pursche L, Hatiboglu G, Nyarangi-Dix J, Sültmann H, Zschäbitz S, Koerber SA, Jäger D, Debus J, Duensing A, Schirmacher P, Hohenfellner M, Stenzinger A, Duensing S. Nientiedt C, et al. Among authors: duensing a, duensing s. Urol Oncol. 2022 Jan;40(1):8.e11-8.e18. doi: 10.1016/j.urolonc.2021.06.024. Epub 2021 Jul 26. Urol Oncol. 2022. PMID: 34325986 Free article.
Centrosomes, polyploidy and cancer.
Duensing A, Duensing S. Duensing A, et al. Among authors: duensing s. Adv Exp Med Biol. 2010;676:93-103. doi: 10.1007/978-1-4419-6199-0_6. Adv Exp Med Biol. 2010. PMID: 20687471 Review.
High-risk prostate cancer: a disease of genomic instability.
Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, Duensing S. Tapia-Laliena MA, et al. Among authors: duensing s. Urol Oncol. 2014 Nov;32(8):1101-7. doi: 10.1016/j.urolonc.2014.02.005. Epub 2014 Jun 13. Urol Oncol. 2014. PMID: 24931269 Review.
211 results